Insights

Innovation in Longevity Oisin Biotechnologies specializes in developing genetic medicines targeting senescent cells to combat age-related diseases, presenting a unique opportunity for partners interested in cutting-edge longevity and anti-aging therapeutics.

Recent Funding Success With a recent $15 million Series A funding round, Oisin demonstrates strong investor confidence, indicating potential for expansion and increased R&D activity that could benefit suppliers, collaborators, or service providers in biotech development.

Growing Focus on Aging Markets As a company actively developing therapies for age-related conditions, there are significant sales opportunities in partnering for research tools, clinical trial support, and commercialization services tailored to aging and longevity markets.

Technological Sophistication Utilizing modern tech stacks such as data analytics and cloud services, Oisin may require advanced IT infrastructure, data management, and cybersecurity solutions to support their R&D activities and product development.

Strategic Industry Positioning Compared to established biotech firms with larger staff and revenue, Oisin's niche focus and innovative approach position it as a promising partner for early adoption of new therapies and collaborative research projects in the longevity space.

Similar companies to Oisin Biotechnologies

Oisin Biotechnologies Tech Stack

Oisin Biotechnologies uses 8 technology products and services including Squarespace, Apple iCloud Mail, Google Fonts API, and more. Explore Oisin Biotechnologies's tech stack below.

  • Squarespace
    Content Management System
  • Apple iCloud Mail
    Email
  • Google Fonts API
    Font Scripts
  • Modernizr
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • Google Maps
    Maps
  • YouTube
    Video Players
  • Google Analytics
    Web Analytics

Oisin Biotechnologies's Email Address Formats

Oisin Biotechnologies uses at least 1 format(s):
Oisin Biotechnologies Email FormatsExamplePercentage
First.Last@oisinbio.comJohn.Doe@oisinbio.com
45%
First.Middle@oisinbio.comJohn.Michael@oisinbio.com
5%
First.Last@oisinbio.comJohn.Doe@oisinbio.com
45%
First.Middle@oisinbio.comJohn.Michael@oisinbio.com
5%

Frequently Asked Questions

Where is Oisin Biotechnologies's headquarters located?

Minus sign iconPlus sign icon
Oisin Biotechnologies's main headquarters is located at 800 5th Avenue, Suite 4100. The company has employees across 2 continents, including North AmericaEurope.

What is Oisin Biotechnologies's official website and social media links?

Minus sign iconPlus sign icon
Oisin Biotechnologies's official website is oisinbio.com and has social profiles on LinkedInCrunchbase.

What is Oisin Biotechnologies's SIC code NAICS code?

Minus sign iconPlus sign icon
Oisin Biotechnologies's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Oisin Biotechnologies have currently?

Minus sign iconPlus sign icon
As of January 2026, Oisin Biotechnologies has approximately 17 employees across 2 continents, including North AmericaEurope. Key team members include Cso: J. L.Director: J. R.Advisory Board Member: C. G. R.. Explore Oisin Biotechnologies's employee directory with LeadIQ.

What industry does Oisin Biotechnologies belong to?

Minus sign iconPlus sign icon
Oisin Biotechnologies operates in the Biotechnology Research industry.

What technology does Oisin Biotechnologies use?

Minus sign iconPlus sign icon
Oisin Biotechnologies's tech stack includes SquarespaceApple iCloud MailGoogle Fonts APIModernizrjQueryGoogle MapsYouTubeGoogle Analytics.

What is Oisin Biotechnologies's email format?

Minus sign iconPlus sign icon
Oisin Biotechnologies's email format typically follows the pattern of First.Last@oisinbio.com. Find more Oisin Biotechnologies email formats with LeadIQ.

How much funding has Oisin Biotechnologies raised to date?

Minus sign iconPlus sign icon
As of January 2026, Oisin Biotechnologies has raised $10M in funding. The last funding round occurred on Aug 01, 2025 for $10M.

When was Oisin Biotechnologies founded?

Minus sign iconPlus sign icon
Oisin Biotechnologies was founded in 2014.

Oisin Biotechnologies

Biotechnology ResearchWashington, United States11-50 Employees

Oisin Biotechnologies is a longevity therapeutics platform company focused on creating genetic medicines to combat a variety of age related diseases.

When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function.

Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases.

Oisín Biotechnologies is developing a highly precise, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.

Section iconCompany Overview

Headquarters
800 5th Avenue, Suite 4100
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
11-50

Section iconFunding & Financials

  • $10M

    Oisin Biotechnologies has raised a total of $10M of funding over 6 rounds. Their latest funding round was raised on Aug 01, 2025 in the amount of $10M.

  • $1M$10M

    Oisin Biotechnologies's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $10M

    Oisin Biotechnologies has raised a total of $10M of funding over 6 rounds. Their latest funding round was raised on Aug 01, 2025 in the amount of $10M.

  • $1M$10M

    Oisin Biotechnologies's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.